Latest

What has Pharma Learned from the Merck Cyber Attack

One year after the Merck cyber attack pharma takes stock of what the industry has learned and what to do moving forward.

Machine Learning: The Next Frontier in Commercial Planning

Keshia Maughn looks at how machine learning can transform commercial planning and outlines what teams will need to deploy it effectively.

Developing Mindful Pharma Leaders

Mindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.

Patent Protection for Cannabis?

Amid a still-difficult environment for enforcing cannabis-related patents, Eric Furman and Ari Feinstein explore the types of patent protection available for cannabis-based therapies and inventions.

Pharm Exec Video

Behind the Scenes with Kallyope’s Nancy Thornberry

A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.

Why One Korean Biotech Picked New Jersey for U.S. Headquarters

New Jersey is still a top pick for companies when it comes to pharma.

Pharm Exec Talks Partnerships with Sanofi

Hear what Sanofi looks for when they decide to form a partnership with another company.

New & Noteworthy

Healthcare Marketers: Being More Human Doesn’t Mean Being Less Transparent

Like Facebook, many healthcare companies are trying to become more "like people". They should instead prioritize transparency and engaging in knowledge-sharing with the public, writes Julia Stern.

Biopharma Business Check

The increase in new drug approvals and candidates in development are good signs for pharma & biotech, but both sectors face continued pricing, cost, and policy-related challenges, writes Peter Young.

High-Risk Marketing Violations Draw Scrutiny

Regulators, prosecutors shifting enforcement focus from off-label promotion to messages that raise safety issues, mislead. Jill Wechsler reports.

Diabetes Researchers Make Novel Connections with Graph Technology

Emil Eifrem examines how researchers at Munich’s German Center for Diabetes Research are uncovering insights with a new way of working with complex data.

Patent Protection for Cannabis?

Amid a still-difficult environment for enforcing cannabis-related patents, Eric Furman and Ari Feinstein explore the types of patent protection available for cannabis-based therapies and inventions.

Sales & Marketing

Healthcare Marketers: Being More Human Doesn’t Mean Being Less Transparent

Like Facebook, many healthcare companies are trying to become more "like people". They should instead prioritize transparency and engaging in knowledge-sharing with the public, writes Julia Stern.

High-Risk Marketing Violations Draw Scrutiny

Regulators, prosecutors shifting enforcement focus from off-label promotion to messages that raise safety issues, mislead. Jill Wechsler reports.

Social Science Behavior Change Models: The Key to More Targeted Messages

Charles Daramola discusses the application of social science behavior change theories and models to physician sales.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Steadying the Path of Good Science

As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

Southeast Biotech: Rising Tall in the Valley

Michelle Maskaly examines the booming life sciences scene in southeast Virginia and Raleigh-Durham and Winston-Salem, North Carolina—and the region’s advantages in location, talent, and funding compared to the more glamour spots up north.

Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and Cannabis

Analysts from Pharma Intelligence take a deeper dive into these three pivotal areas of R&D today—the crisis points and progress.

Stunted Innovation in Drug Development?

Data shows cultural gaps and highlights a C-level fix, writes Meghan Oates-Zalesky.

Interviews

Of Mice and mAbs: Dr. Larry Green, Ablexis

Ablexis CEO and AlivaMab Mouse co-inventor Larry Green tells PharmExec about the evolution of the company and the main challenges associated with the pre-clinical discovery of monoclonal antibodies.

Bridging R&D and IP: Anjum Swaroop, Dr. Reddy's

Anjum Swaroop, Vice President and Head of IP at Dr. Reddy's, talks about her journey with the company and about what the future holds for this major US generics player.

ESMO Spotlight: James Campbell, Merck KGaA, Darmstadt, Germany

Pharm Exec speaks to James Campbell—global franchise business head at Merck KGaA, Darmstadt, Germany—to discuss his vision for the company as a global leader in oncology.

Regulatory

Split Congress to Attack Drug Pricing

Healthcare was the deciding issue for more than 40 percent of voters in the mid-term elections. Despite disagreement on most of the issues, leaders of the two parties are open to challenging the status quo on drug costs and spending.

International Reference Pricing, US Style

President Trump's International Pricing Index proposals amount to international reference pricing (IRP), something that countries in Europe have been doing for years. What lessons can be learned from there?

RMAT Designations: Lessons Learned on the “Clinical Evidence” Requirement

The Regenerative Medicine Advanced Therapies (RMAT) designation was introduced as a pathway to accelerate FDA approval and market entry of regenerative medical therapies. Two years on, William Rose and Suchira Ghosh identify the trends in how FDA assesses the clinical evidence supporting successful RMAT candidates.

FDA's $100 Million RWE Project: Making It All It Can Be

FDA's proposal to gather real-world evidence from 10 million individuals could have profound implications, but the Agency needs to take a more expansive view of what RWE can be, writes Paul Glimcher.

From the Editor

Steadying the Path of Good Science

As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

Getting Where You Need to Go

As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.

lorem ipsum